{"id":6027,"date":"2024-01-04T10:00:44","date_gmt":"2024-01-04T01:00:44","guid":{"rendered":"https:\/\/hbio.jp\/news\/?p=6027"},"modified":"2024-04-04T16:37:21","modified_gmt":"2024-04-04T07:37:21","slug":"20240104-2","status":"publish","type":"post","link":"https:\/\/hbio.jp\/news\/en\/2024\/01\/04\/20240104-2\/","title":{"rendered":"Nematode cancer test \u201cN-NOSE\u201d exceeds 2,000 companies"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>HIROTSU Bio\nScience Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu\n(Hereinafter referred to as \u201cHIROTSU\u201d)), is proud to announce<\/strong> <strong>that the total number of companies that\nhave adopted N-NOSE has exceeded 2,000.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It is currently a challenge for\nindividuals to take cancer control measures on their own, both financially and\nmentally. However, companies can protect their valuable employees by\nrecommending it as a benefit program.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Our &#8220;N-NOSE&#8221; program began\nto be introduced in companies in April 2022, and about 70 companies have\nintroduced it every month. In particular, many companies with irregular working\nhours, such as those in the construction and transportation industries, have\nintroduced the system because &#8220;employees can decide where and when they\nwant to submit their documents on their own. We are honored to be able to help\nsolve this problem, as &#8220;lack of time&#8221; is one of the major reasons why\npeople do not take cancer screenings<sup>*1<\/sup>. We will continue our efforts\nto solve various issues for the future of early cancer detection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">*1\u3000Cabinet Office, 2023. \u201d\u304c\u3093\u5bfe\u7b56\u306b\u95a2\u3059\u308b\u4e16\u8ad6\u8abf\u67fb\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u25a0Company Employee Testimonials<br>About 10 years ago, I had a biopsy for prostate cancer with high PSA, but there was no problem and I was under observation. This year, my PSA level became high, and I was told to have a detailed examination. About 2 years ago, N-NOSE was introduced as a company benefit program, and I knew someone who was found to have early-stage colorectal cancer through a precision examination because of the risk assessment. The result was a D grade. After that, I requested a biopsy at a general hospital and found early-stage prostate cancer. <br>The surgery took about 4 hours, and I was hospitalized for 9 days. If treated early, there is no need to stay in bed. It would be good if a simple examination is done first and leads to early detection. It would be good if it spreads more and more to corporate health checkups.<br>(Male, suffering from prostate cancer)<\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/hbio.jp\/news\/wp-content\/uploads\/2024\/04\/\u3010PressRelease\u3011Nematode-cancer-test-\u201cN-NOSE\u201d-exceeds-2000-companies_20240404.pdf\">Download PDF<\/a><a href=\"https:\/\/hbio.jp\/news\/wp-content\/uploads\/2024\/04\/\u3010PressRelease\u3011Nematode-cancer-test-\u201cN-NOSE\u201d-exceeds-2000-companies_20240404.pdf\" class=\"wp-block-file__button\" download><\/a><\/div>","protected":false},"excerpt":{"rendered":"<p>HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referre [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"6027","footnotes":""},"categories":[3],"tags":[],"class_list":["post-6027","post","type-post","status-publish","format-standard","hentry","category-press-release","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/comments?post=6027"}],"version-history":[{"count":2,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6027\/revisions"}],"predecessor-version":[{"id":6030,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6027\/revisions\/6030"}],"wp:attachment":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/media?parent=6027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/categories?post=6027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/tags?post=6027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}